Breaking News
December 16, 2017 - Research uncovers mechanism implicated in defective function of tumor-associated dendritic cells
December 16, 2017 - OncoBreak: Stubborn Racial Disparities; Paid Medical Leave & Chemo; DIY Gene Tests
December 16, 2017 - Critical link between obesity and diabetes has been identified
December 16, 2017 - Transfusion dependence reduces access to high-quality end-of-life care for leukemia patients
December 16, 2017 - Porvair and Suzhou Tianlong Bio to develop epigenetic analysis technologies
December 16, 2017 - FDA Approves Ixifi (infliximab-qbtx), a Biosimilar to Remicade
December 16, 2017 - Morning Break: Trump to Get Check-Up; Cancerous Transplant; Death Knell for MIPS?
December 16, 2017 - First transcatheter implant for diastolic heart failure successful
December 16, 2017 - ‘Sushi-like’ nanodiscs provide structural snapshots of misfolding proteins
December 16, 2017 - Inherited gene variation may be to blame for poor survival of patients with early-onset breast cancer
December 16, 2017 - Sign-up deadline is Friday, but some people may get extra time
December 16, 2017 - Higher Booze Taxes Might Pay Off for Public Health
December 16, 2017 - Regular Activity in Midlife Spares Joints in Women
December 16, 2017 - Rain May Not Cause Achy Joints After All: MedlinePlus Health News
December 16, 2017 - MedDiet adherence doesn’t affect acute heart failure mortality
December 16, 2017 - HKBU experts develop new generation of smart anti-cancer drug molecules
December 16, 2017 - Chronic Kidney Disease Audit finds wide variations in coding of CKD patients in primary care
December 16, 2017 - Scientists use nanoparticles to fight Mucoviscidosis
December 16, 2017 - Increasing physical activity decreases risk of death from lymphoma
December 16, 2017 - Fear compromises the health, well-being of immigrant families, survey finds
December 16, 2017 - Rejected antibiotic candidate could be worth a second look, research finds
December 16, 2017 - Is Nation on the Right Track to Combat Opioid Crisis?
December 16, 2017 - Arthritis No Longer Just a Disease of the Old: MedlinePlus Health News
December 16, 2017 - Family members without inherited mutation have increased risk of melanoma
December 16, 2017 - Active surveillance proposed as first-line approach to manage patients with low-risk PMC of the thyroid
December 16, 2017 - Patients’ life values affect their attendance at medical treatment for pelvic-floor dysfunction
December 16, 2017 - Experts consider hazards of antibiotic resistances to be high
December 16, 2017 - Study finds erectile dysfunction as risk factor for early cardiovascular disease
December 16, 2017 - Amber-tinted glasses may reduce insomnia severity
December 16, 2017 - Arthritis Drug Seen Lowering GvHD Risk
December 16, 2017 - Atoh1, a potential Achilles’ heel of Sonic Hedgehog medulloblastoma
December 15, 2017 - Cornell engineers develop new method to measure vital signs using radio waves
December 15, 2017 - Rutgers studies highlight need for salon clients, workers to protect themselves from health risks
December 15, 2017 - FDA Approves Nucala (mepolizumab) for Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss Syndrome)
December 15, 2017 - Morning Break: CVS Buying Aetna; Uterus Transplant Baby; Your Brain on Drugs, Redux
December 15, 2017 - Social phobia linked to autism and schizophrenia
December 15, 2017 - Timestrip technology helping to prevent missed vaccinations
December 15, 2017 - Researchers win NIH grants for Alzheimer’s research on Amish resilience and rapid onset
December 15, 2017 - Mitochondrial error-correction mechanism essential for energy production of cells
December 15, 2017 - New report reveals steep rise in lung disease admissions to emergency departments during winter
December 15, 2017 - Study finds social stigma as barrier to successful treatment of children with HIV in Ethiopia
December 15, 2017 - Health Tip: Keep Gift-Giving Stress Under Wraps
December 15, 2017 - Long Stoppage of Bisphosphonates Tied to More Fractures
December 15, 2017 - Triglycerides Test: MedlinePlus Lab Test Information
December 15, 2017 - Study shows interventions, though few, can be effective for students with high-functioning autism
December 15, 2017 - Higher blood sugar during first trimester of pregnancy increases child’s risk of congenital heart defect
December 15, 2017 - Study tests accuracy of laboratory-developed cancer tests and FDA-approved companion diagnostics
December 15, 2017 - Extracellular vesicles can be used to effectively delay progression of kidney damage
December 15, 2017 - Targeted lung cancer treatments may benefit smokers and non-smokers alike
December 15, 2017 - Sugary-drink warning labels may help decrease obesity and overweight prevalence
December 15, 2017 - Coarse particulate matter exposure linked to increased asthma risk in children
December 15, 2017 - OCT Angio Gains Ground: Ophthalmology Times
December 15, 2017 - Flu Can Have Dangerous Domino Effect on Older Adults: MedlinePlus Health News
December 15, 2017 - A daily cup of hot tea may lower glaucoma risk
December 15, 2017 - New blood test accurately forecasts advanced heart failure patients’ survival after surgery
December 15, 2017 - Study finds improvements in survivals rates of individuals with kidney failure
December 15, 2017 - Rare gene mutation gives rise to low sensitivity to pain
December 15, 2017 - Older Women Do Well with New Breast Cancer Drugs
December 15, 2017 - Joint damage in healthy military recruits may mimic spondyloarthropathies
December 15, 2017 - Researchers examine link between tumor mutational burden and response to immune checkpoint therapy
December 15, 2017 - Nanotextured surfaces kill bacteria without harming mammalian cells
December 15, 2017 - Ketamine more effective than common sedative in reducing suicidal thoughts
December 15, 2017 - Scientists engineer light-emitting plant
December 15, 2017 - Medicare fails to recover hundreds of millions of dollars in lab overcharges
December 15, 2017 - IPM begins first clinical trial of vaginal rings to prevent HIV in women
December 15, 2017 - Telemedicine for addiction treatment? Picture remains fuzzy
December 15, 2017 - Genetic variations may help identify people at high-risk for chronic pain after surgery
December 15, 2017 - Intersect ENT Announces FDA Approval of Sinuva (mometasone furoate) Sinus Implant, a New In-Office Treatment Option for Recurrent Nasal Polyps
December 15, 2017 - Learning the Lessons of FluMist
December 15, 2017 - Study shows brain structures make some people resilient to Alzheimer’s disease
December 15, 2017 - UQ researchers create new and improved version of ‘love hormone’
December 15, 2017 - Anti-stress compounds provide new treatment approach for diabetes and obesity
December 15, 2017 - Survey finds extremely high rate of mortality from sepsis in ICUs
December 15, 2017 - Study provides insights into molecular mechanisms regulating cellular fate of SCCs
December 15, 2017 - Researchers identify previously unknown functions of natural killer cells in the womb
December 15, 2017 - Tech at Bedtime May Mean Heavier Kids
December 15, 2017 - Meta-Analysis: Hearing Loss Linked to Dementia in Elderly
December 15, 2017 - Second Phase 3 study results for LMTX published
December 15, 2017 - Researchers team up to identify vulnerabilities of lethal parasite
December 15, 2017 - Experts call for more action on gambling-related research and treatment
FDA approves first adjuvant treatment to reduce risk of kidney cancer recurrence

FDA approves first adjuvant treatment to reduce risk of kidney cancer recurrence

image_pdfDownload PDFimage_print

The U.S. Food and Drug Administration today approved Sutent (sunitinib malate) for the adjuvant treatment of adult patients who are at a high risk of kidney cancer (renal cell carcinoma) returning after a kidney has been removed (nephrectomy). Adjuvant treatment is a form of therapy that is taken after an initial surgical removal to lower the risk of the cancer coming back.

“This is the first adjuvant treatment approved for patients with renal cell carcinoma, which is significant because patients with this disease who have a nephrectomy are often at high risk of the cancer returning,” said Richard Pazdur, M.D., director of the FDA’s Oncology Center of Excellence and acting director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “There is now an approved therapy for patients who previously did not have options to potentially reduce cancer recurrence.”

The National Cancer Institute (NCI) at the National Institutes of Health estimates approximately 63,990 patients will be diagnosed with kidney and renal cell pelvis cancer this year, and 14,440 will die of the disease.

Sutent is a kinase inhibitor that works by blocking several enzymes that promote cell growth. Sutent was first approved in 2006 for the treatment of certain patients with gastrointestinal stromal tumors and advanced renal cell carcinoma. It is also approved for patients with a certain type of pancreatic cancer.

The approval of Sutent for the adjuvant treatment of renal cell carcinoma was based on a randomized trial of 615 patients with high risk of recurrent renal cell carcinoma following nephrectomy. The study measured the amount of time after the start of the trial that it took for the cancer to come back, for the patient to develop another unrelated cancer, or for death to occur from any cause (disease-free survival). After five years, 59.3 percent of patients treated with Sutent had not experienced cancer recurrence or death compared with 51.3 percent of patients receiving placebo.

Common side effects of Sutent include fatigue, diarrhea, inflammation of the mucous membranes and inside the mouth (mucositis/stomatitis), nausea, decreased appetite/anorexia, vomiting, abdominal pain, skin reactions on the hands and feet (hand-foot syndrome), high blood pressure (hypertension), bleeding events, altered taste (dysgeusia), indigestion (dyspepsia) and low levels of blood platelets (thrombocytopenia).

Severe side effects of Sutent include severe liver damage (hepatotoxicity), heart failure (low left ventricular ejection fraction), heart attack (myocardial ischemia/infarction), abnormal health rhythm (prolonged QT intervals/Torsade de Pointes), hypertension, bleeding (hemorrhagic events), metabolic abnormalities due to breakdown of the tumor (tumor lysis syndrome), blood vessel abnormalities leading to blood clots in the small blood vessels resulting in low platelet counts and organ dysfunction (thrombotic microangiopathy, including thrombotic thrombocytopenic purpura and hemolytic uremic syndrome), high levels of protein in the urine (proteinuria), thyroid dysfunction, low blood sugar (hypoglycemia), breakdown of the bone of the jaw due to loss of blood supply (osteonecrosis), and wound healing complications. Patients should stop taking Sutent if serious skin reactions occur (necrotizing fasciitis, erythema multiforme, Stevens-Johnson syndrome or toxic epidermal necrolysis). Women who are pregnant should not take Sutent because it may cause harm to a developing fetus.

The labeling for Sutent contains a boxed warning to alert healthcare professionals and patients about the risk of severe liver damage (hepatoxicity), which may result in liver failure or death.

The FDA granted the approval of Sutent to Pfizer Inc.

Source:

https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm585657.htm

Tagged with:

About author

Related Articles